Biogen (BIIB) said Wednesday that the US Food and Drug Administration has granted fast track designation to its investigational antisense oligonucleotide therapy BIIB080 aimed at treating Alzheimer's disease.
The company said BIIB080 is the first tau-targeting ASO therapy to enter clinical development for Alzheimer's and is currently being evaluated in a global phase 2 study in individuals with early-stage disease.
Biogen said the phase 2 trial is fully enrolled and a data readout is expected in 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。